Aspira Womens Health Inc - AWH STOCK NEWS

Welcome to our dedicated page for Aspira Womens Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Womens Health stock.

Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.

One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.

In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.

The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.

Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.

The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.

12/14/2023 08:00 AM

News

Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024

Rhea-AI Summary

Aspira Women’s Health Inc. (AWH) will be available for meetings in San Francisco from January 8-10, 2024, during JP Morgan’s Healthcare Conference Week. Nicole Sandford, President and CEO, and Torsten Hombeck, CFO, will be attending the 12th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright & Co. Hosted Investor Meetings for partnering and institutional one-on-one meetings. Aspira is a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.48%

Tags

12/06/2023 08:00 AM

News

Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) has developed EndoCheck, the first blood test for identifying localized endometriosis, including endometrioma, with plans for a commercial launch in 2024. The test is expected to offer a non-invasive alternative to laparoscopic surgery for endometriomas, potentially addressing a market of up to 2.5 million women in the U.S. The company is also working on the development of EndoMDx, a broader test for all types and locations of endometriosis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.69%

Tags

11/28/2023 08:00 AM

News

Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

Rhea-AI Summary

Aspira Women’s Health Inc. (AWH) announced that California Medicaid (Medi-Cal) added Ova1Plus® to its fee schedule at $897 per test. Aspira will be reimbursed at a rate of $897 for all Ova1Plus® tests processed for Medi-Cal patients meeting applicable coverage requirements, effective from October 15, 2023. The addition of Ova1Plus® to the fee schedule provides expanded access to this groundbreaking technology for women in California facing an ovarian cancer diagnosis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.6%

Tags

11/27/2023 09:47 AM

News

Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Rhea-AI Summary

Aspira Women’s Health Inc. (AWH) receives CMS approval for OvaWatch 2024 price at $897 per test. The Centers for Medicare & Medicaid Services (CMS) has approved the reimbursement rate for OvaWatch and Ova1 tests processed for Medicare patients, beginning January 1, 2024. Aspira's President and CEO, Nicole Sandford, emphasizes the importance of reliable clinical data in ovarian cancer diagnosis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.78%

Tags

11/13/2023 04:05 PM

News

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) reported a 9% increase in product revenue to $2.2 million for the quarter and a 19% increase to $7.0 million year to date. OvaSuite sales volume increased 5% to 5,783 units for the quarter and 16% to 18,331 units year to date. The company also highlighted significant achievements in the development of new products and the establishment of a Clinical Advisory Board.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.6%

Tags

11/09/2023 08:00 AM

News

Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announces that CMS has proposed to crosswalk the reimbursement rate for OvaWatch to Ova1 at $897 per test, pending finalization in January 2024. This move supports Aspira's mission to gain broad reimbursement coverage for their non-invasive ovarian cancer identification tests.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.34%

Tags

10/31/2023 08:00 AM

News

Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023

Rhea-AI Summary

Aspira Women’s Health Inc. will report its financial results for the three months ended September 30, 2023 on November 13, 2023. The company will host a conference call with investors at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Participants can join the call using the provided toll-free and international numbers or access the event instantly through the Call me™ link. A replay of the webcast will be available on the company's Investor Relations website.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.28%

Tags

10/25/2023 08:00 AM

News

Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Rhea-AI Summary

Aspira Women’s Health announces promising findings on an in-development miRNA-based ovarian cancer test. The study shows that miRNA has the potential to improve the diagnostic accuracy of non-invasive diagnostic tests for early-stage ovarian cancers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.08%

Tags

10/23/2023 08:00 AM

News

Aspira Women’s Health Establishes a New Clinical Advisory Board

Rhea-AI Summary

Aspira Women’s Health Inc. has established a Clinical Advisory Board to develop and distribute diagnostic tools for gynecologic diseases. The board consists of preeminent physicians with deep clinical expertise in gynecologic health.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.12%

Tags

09/29/2023 08:00 AM

News

Aspira Women’s Health to Present at the BioVenture Nexus Conference

Rhea-AI Summary

Aspira Women’s Health Inc. will present a brief corporate overview at the BioVenture Nexus Conference on October 5, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.68%

Tags

FAQ

What is the current stock price of Aspira Womens Health (AWH)?

The current stock price of Aspira Womens Health (AWH) is $0.22 as of February 21, 2025.

What is the market cap of Aspira Womens Health (AWH)?

The market cap of Aspira Womens Health (AWH) is approximately 4.0M.

What is Aspira Women's Health Inc. known for?

Aspira Women's Health Inc. is known for developing and commercializing noninvasive diagnostic tests for gynecologic diseases, particularly ovarian cancer.

What products does Aspira offer?

Aspira offers OvaSuite, which includes OvaWatch and Ova1Plus. These are blood tests designed to assess the risk of ovarian cancer in women with adnexal masses.

How effective is OvaWatch?

OvaWatch has a negative predictive value of 99%, making it highly effective in assessing ovarian cancer risk in women with indeterminate or benign adnexal masses.

What is Ova1Plus?

Ova1Plus is a combination of two FDA-cleared tests, Ova1® and Overa®, designed to assess the risk of ovarian malignancy in women planned for surgery.

What recent achievements has Aspira made?

Aspira has recently published significant clinical studies, secured Anthem Blue Cross payer coverage, and reduced operational cash use while increasing revenues and test volumes.

What is EndoCheck?

EndoCheck is the first-ever noninvasive test developed by Aspira to identify endometriomas, a common form of endometriosis.

How has Aspira performed financially recently?

In 2023, Aspira reduced its operational cash use, increased revenues, and achieved key market access milestones. They also raised $5.5 million through a direct offering and private placement.

Who leads Aspira Women's Health Inc.?

Aspira is led by CEO Nicole Sandford, who has guided the company through significant growth and innovation in women's health diagnostics.

What is OvaMDx?

OvaMDx is an in-development test that combines microRNA and protein biomarkers with patient data to enhance the sensitivity and specificity of ovarian cancer risk assessments.

How does Aspira's test pipeline address women's health issues?

Aspira's test pipeline, including EndoCheck and OvaMDx, aims to provide noninvasive diagnostic solutions for ovarian cancer and endometriosis, improving care and outcomes for millions of women.